Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Kaela O'BRIEN |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study / Logan K. WINK in Journal of Autism and Developmental Disorders, 51-4 (April 2021)
[article]
Titre : Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study Type de document : Texte imprimé et/ou numérique Auteurs : Logan K. WINK, Auteur ; Debra L. REISINGER, Auteur ; Paul HORN, Auteur ; Rebecca C. SHAFFER, Auteur ; Kaela O'BRIEN, Auteur ; Lauren M. SCHMITT, Auteur ; Kelli R. DOMINICK, Auteur ; Ernest V. PEDAPATI, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.1392-1399 Langues : Anglais (eng) Mots-clés : Autism Clinical trial Ketamine Index. décimale : PER Périodiques Résumé : Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose, double-blind, placebo controlled, cross-over pilot trial of intranasal (IN) ketamine targeting core social impairment included individuals with ASD (N?=?21) between 14 and 29 years. Participants were randomized to received two doses of IN ketamine (30 and 50 mg) and two doses of matching placebo. No significant impact was noted on the Aberrant Behavior Checklist Social Withdraw subscale. The IN ketamine was well tolerated, with only transient mild adverse effects. En ligne : http://dx.doi.org/10.1007/s10803-020-04542-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=445
in Journal of Autism and Developmental Disorders > 51-4 (April 2021) . - p.1392-1399[article] Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study [Texte imprimé et/ou numérique] / Logan K. WINK, Auteur ; Debra L. REISINGER, Auteur ; Paul HORN, Auteur ; Rebecca C. SHAFFER, Auteur ; Kaela O'BRIEN, Auteur ; Lauren M. SCHMITT, Auteur ; Kelli R. DOMINICK, Auteur ; Ernest V. PEDAPATI, Auteur ; Craig ERICKSON, Auteur . - p.1392-1399.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 51-4 (April 2021) . - p.1392-1399
Mots-clés : Autism Clinical trial Ketamine Index. décimale : PER Périodiques Résumé : Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose, double-blind, placebo controlled, cross-over pilot trial of intranasal (IN) ketamine targeting core social impairment included individuals with ASD (N?=?21) between 14 and 29 years. Participants were randomized to received two doses of IN ketamine (30 and 50 mg) and two doses of matching placebo. No significant impact was noted on the Aberrant Behavior Checklist Social Withdraw subscale. The IN ketamine was well tolerated, with only transient mild adverse effects. En ligne : http://dx.doi.org/10.1007/s10803-020-04542-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=445